180 related articles for article (PubMed ID: 27812217)
1. Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania.
Wyllie S; Roberts AJ; Norval S; Patterson S; Foth BJ; Berriman M; Read KD; Fairlamb AH
PLoS Pathog; 2016 Nov; 12(11):e1005971. PubMed ID: 27812217
[TBL] [Abstract][Full Text] [Related]
2. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.
Wyllie S; Patterson S; Stojanovski L; Simeons FR; Norval S; Kime R; Read KD; Fairlamb AH
Sci Transl Med; 2012 Feb; 4(119):119re1. PubMed ID: 22301556
[TBL] [Abstract][Full Text] [Related]
3. Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation.
Wyllie S; Patterson S; Fairlamb AH
Antimicrob Agents Chemother; 2013 Feb; 57(2):901-6. PubMed ID: 23208716
[TBL] [Abstract][Full Text] [Related]
4. Current and Future Prospects of Nitro-compounds as Drugs for Trypanosomiasis and Leishmaniasis.
Patterson S; Fairlamb AH
Curr Med Chem; 2019; 26(23):4454-4475. PubMed ID: 29701144
[TBL] [Abstract][Full Text] [Related]
5. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives.
Wilkinson SR; Bot C; Kelly JM; Hall BS
Curr Top Med Chem; 2011; 11(16):2072-84. PubMed ID: 21619510
[TBL] [Abstract][Full Text] [Related]
6. Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei.
Wyllie S; Foth BJ; Kelner A; Sokolova AY; Berriman M; Fairlamb AH
J Antimicrob Chemother; 2016 Mar; 71(3):625-34. PubMed ID: 26581221
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of nitro drugs metronidazole and nitazoxanide in Giardia lamblia: characterization of a novel nitroreductase (GlNR2).
Müller J; Schildknecht P; Müller N
J Antimicrob Chemother; 2013 Aug; 68(8):1781-9. PubMed ID: 23580565
[TBL] [Abstract][Full Text] [Related]
8. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites.
Hall BS; Bot C; Wilkinson SR
J Biol Chem; 2011 Apr; 286(15):13088-95. PubMed ID: 21345801
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; O'Shea IP; Wilkinson SR; Kaiser M; Chatelain E; Ioset JR
Bioorg Med Chem; 2015 Oct; 23(19):6467-76. PubMed ID: 26344593
[TBL] [Abstract][Full Text] [Related]
10. Identification of Enterococcus faecalis enzymes with azoreductases and/or nitroreductase activity.
Chalansonnet V; Mercier C; Orenga S; Gilbert C
BMC Microbiol; 2017 May; 17(1):126. PubMed ID: 28545445
[TBL] [Abstract][Full Text] [Related]
11. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs.
Maia C; Nunes M; Marques M; Henriques S; Rolão N; Campino L
Exp Parasitol; 2013 Sep; 135(1):36-41. PubMed ID: 23747751
[TBL] [Abstract][Full Text] [Related]
12. Nitroreductase (GlNR1) increases susceptibility of Giardia lamblia and Escherichia coli to nitro drugs.
Nillius D; Müller J; Müller N
J Antimicrob Chemother; 2011 May; 66(5):1029-35. PubMed ID: 21393225
[TBL] [Abstract][Full Text] [Related]
13. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India.
Mandal S; Maharjan M; Singh S; Chatterjee M; Madhubala R
J Antimicrob Chemother; 2010 Mar; 65(3):496-507. PubMed ID: 20067981
[TBL] [Abstract][Full Text] [Related]
14. Delamanid is not metabolized by Salmonella or human nitroreductases: A possible mechanism for the lack of mutagenicity.
Hanaki E; Hayashi M; Matsumoto M
Regul Toxicol Pharmacol; 2017 Mar; 84():1-8. PubMed ID: 27988333
[TBL] [Abstract][Full Text] [Related]
15. Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
Gupta S; Yardley V; Vishwakarma P; Shivahare R; Sharma B; Launay D; Martin D; Puri SK
J Antimicrob Chemother; 2015 Feb; 70(2):518-27. PubMed ID: 25389223
[TBL] [Abstract][Full Text] [Related]
16. Functional Involvement of Leishmania donovani Tryparedoxin Peroxidases during Infection and Drug Treatment.
Das S; Giri S; Sundar S; Shaha C
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061756
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics.
Kumari S; Kumar A; Samant M; Singh N; Dube A
Curr Drug Targets; 2008 Nov; 9(11):938-47. PubMed ID: 18991606
[TBL] [Abstract][Full Text] [Related]
18. In Vitro and In Vivo Effectiveness of Carvacrol, Thymol and Linalool against
Youssefi MR; Moghaddas E; Tabari MA; Moghadamnia AA; Hosseini SM; Farash BRH; Ebrahimi MA; Mousavi NN; Fata A; Maggi F; Petrelli R; Dall'Acqua S; Benelli G; Sut S
Molecules; 2019 May; 24(11):. PubMed ID: 31151304
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Leishmania infantum pyridoxal kinase protein for the diagnosis of human and canine visceral leishmaniasis.
Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Ludolf F; Steiner BT; Reis TAR; Santos TTO; Costa LE; Martins VT; Galvani NC; Chaves AT; Oliveira JS; Chávez-Fumagalli MA; de Magalhães-Soares DF; Duarte MC; Menezes-Souza D; Silveira JAG; Moreira RLF; Machado-de-Ávila RA; Tupinambás U; Gonçalves DU; Coelho EAF
Immunol Lett; 2020 Apr; 220():11-20. PubMed ID: 31981576
[TBL] [Abstract][Full Text] [Related]
20. Comparative characterisation of two nitroreductases from Giardia lamblia as potential activators of nitro compounds.
Müller J; Rout S; Leitsch D; Vaithilingam J; Hehl A; Müller N
Int J Parasitol Drugs Drug Resist; 2015 Aug; 5(2):37-43. PubMed ID: 27099829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
